Reply to Guo et al. Dong et al. and Belecanech et al.

Read full text Summarise with VIRAT
Authors: Laurent Savale, Thomas d’Humières, Pablo Bartolucci, Marc J.C. Humbert
Cited by: 0
References: 5

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

From the Authors: We read with great interest the comments on our manuscript “Cardiopulmonary Hemodynamic Determinants of Long-Term Survival in Sickle Cell Disease: Insights from the ETENDARD Study,” which underscore the complexity of the mechanisms underlying pulmonary hemodynamic alterations in sickle cell disease (SCD).1 We agree that elevation of pulmonary artery pressure in SCD results from a wide spectrum of acute, chronic, and treatment-related factors that must be interpreted within their clinical context. The main objective of our study was precisely to clarify the prognostic significance of each hemodynamic parameters by integrating them with patients’ hemolytic profiles and systemic organ involvement. As such, a multiparametric approach is essential for accurate assessment and risk stratification in SCD. Several comments emphasized the interpretative challenges related to pulmonary vascular resistance (PVR) in a high-output state such as SCD. Including PVR in the definition of pre-capillary PH is essential to distinguish elevated pulmonary artery pressure caused by pulmonary vascular disease from that resulting from left heart disease or increased blood flow, all of which can complicate the course of SCD. The PVR threshold of 2 Wood Units (WU) adopted in the updated European guidelines2 derived from large outcome studies,3 may not be directly applicable to all populations. Because PVR is a flow-dependent parameter, it must be interpreted cautiously in SCD. Our study provides new evidence that a lower threshold (≥1.5 WU) more accurately identifies SCD patients at increased risk of mortality. This finding does not challenge current definitions but rather supports a disease-specific refinement that can better detect relevant pulmonary vasculopathy. This distinction is essential to guide clinical decisions. As underlined by Dong et al., we agree that dynamic evaluations such as cardiopulmonary exercise testing could offer deeper insight into early pulmonary vascular disease. We fully acknowledge that assessing patients at a single time point does not exclude the later development of PH. This longitudinal dimension was beyond the scope of the present analysis, which aimed to evaluate the prognostic value of baseline hemodynamic profiles. Nevertheless, the ETENDARD cohort provides a strong foundation for future follow-up studies to characterize the incidence and progression of PH and to determine how evolving organ damage or hemolytic phenotype influencing hemodynamic trajectories. Despite this limitation, our findings reinforce that SCD patients—especially those with renal dysfunction, systemic hypertension, or chronic leg ulcers—represent a high-risk population in whom systematic, preferably annual, screening appears justified. The ETENDARD cohort, with its large number of deeply phenotyped patients, offers a unique opportunity to integrate clinical, biological, and hemodynamic information. Using a random survival forest model, we assessed the combined prognostic contribution of interrelated variables rather than examining each in isolation. This integrative approach demonstrates that mortality risk in SCD-associated PH reflects the cumulative burden of systemic disease severity, hemolysis, and cardiopulmonary dysfunction rather than a single determinant. In this regard, the study moves beyond a reductionist interpretation of PVR and proposes a broader conceptual framework for risk assessment. We also agree that our study does not, at this stage, address the effects of therapeutic interventions on hemodynamic variables, although we and others have previously shown that chronic transfusion therapy can improve pulmonary hemodynamics in SCD.4 As highlighted in the accompanying editorial by Gladwin et al. “the results of this study may help identify therapies that can help mitigate morbidity and mortality associated with PH in patients with SCD.”5 We share this perspective: the ETENDARD study represents an important step toward identifying patients who may benefit from emerging therapeutic strategies and toward structuring future interventional trials in this population, as a new therapeutic era opens for SCD. Future work should aim to longitudinally assess the evolution of these hemodynamic parameters and evaluate the impact of therapeutic interventions over time. Finally, we agree that the issue of access to care for patients with SCD is crucial. This is particularly relevant for a complex condition such as SCD, where many patients lack access to ­expert, centralized, care capable of comprehensive evaluation, including right heart catheterization. Our study confirms that tricuspid regurgitant velocity measurement alone is insufficient to identify high-risk patients. However, we also demonstrated that a non-invasive, multiparametric approach, integrating tricuspid regurgitant velocity with early markers of systemic organ involvement, could effectively stratify risk in SCD when invasive hemodynamic assessment is not feasible. These findings highlight the potential of tailored, non-invasive strategies to improve risk assessment and guide management in patients with limited access to specialized care. All authors have reviewed and approved the final manuscript. Supplementary material is available at American Journal of Respiratory and Critical Care Medicine online. Please see the ICMJE disclosure forms, which have been provided as supplementary material.

Fields of Study & Subjects

Hemoglobinopathies and Related Disorders Pulmonary Hypertension Research and Treatments Congenital Heart Disease Studies

Publication details

Journal / source
American Journal of Respiratory and Critical Care Medicine
Volume
212
Issue
6
Pages
1401–1402
Publication date
25 March 2026
Language
EN